Welcome to our dedicated page for Xencor SEC filings (Ticker: XNCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xencor, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company developing engineered antibody candidates for cancer, autoimmune disease and inflammatory disease. Its Form 8-K disclosures cover financial results, Regulation FD presentations for XmAb942, XmAb412 and the TL1A portfolio, royalty-related disclosures for Ultomiris, and material developments involving collaboration and license agreements.
Proxy materials describe board elections, executive compensation, equity-award information, stockholder voting matters and governance policies. Additional current reports address compensatory arrangements, including executive severance policy disclosures, alongside capital resources and operating-runway information furnished with financial updates.
Xencor Inc ownership filing shows The Vanguard Group reports 0 shares beneficially owned, representing 0% of common stock. The amendment explains an internal realignment effective January 12, 2026 that caused certain subsidiaries to report separately and disaggregate prior holdings.
The filing is signed by Ashley Grim as Head of Global Fund Administration on March 27, 2026 and states The Vanguard Group has no sole or shared voting or dispositive power over Xencor common shares in this report.
Xencor Inc senior executive reports tax-related share sales. SR. Vice President & CSO John R. Desjarlais sold a total of 6,620 shares of Xencor common stock in open-market transactions on March 5 and March 6. The sales were made solely to cover withholding taxes upon vesting of restricted stock units. Following these transactions, he directly holds 263,831 Xencor shares.
Xencor Inc (XNCR) senior vice president and general counsel Celia Eckert reported tax-related sales of company stock. On two days in early March, she sold a total of 5,011 shares of Xencor common stock in open-market transactions at prices around $11 per share.
The footnotes explain these were dispositions of shares sold to pay withholding taxes upon vesting of 7,316 and 4,363 restricted stock units, rather than discretionary share sales. After these transactions, she continued to hold 76,918 Xencor common shares directly.
Xencor Inc. senior vice president and CFO Bart Jan Cornelissen reported an open-market sale of 2,517 shares of common stock on March 5, 2026 at an average price of $11.2455 per share. According to the footnote, these shares were sold to pay withholding taxes upon the vesting of 7,316 restricted stock units, indicating a tax-related transaction rather than a discretionary sale. After this sale, Cornelissen directly holds 79,397 shares of Xencor common stock.
Xencor Inc President and CEO Bassil I. Dahiyat reported selling a total of 21,476 shares of common stock in early March. He sold 14,870 shares on March 5 at an average price of $11.2455 and 6,606 shares on March 6 at $11.0197. According to the footnotes, these dispositions were made to pay withholding taxes upon vesting of 36,581 and 18,179 restricted stock units. After these transactions, he directly owned 546,316 Xencor shares.
Xencor, Inc. reported that Genentech, Inc. and F. Hoffmann-La Roche Ltd are terminating their Amended and Restated Collaboration and License Agreement covering efbalropendekin alfa. Genentech elected to end the agreement for convenience, with termination effective September 4, 2026.
Efbalropendekin alfa, an engineered cytokine-Fc fusion protein, was the sole active collaboration product under the agreement. Roche had already removed it from its development pipeline in connection with its 2024 financial results, and Xencor had earlier opted out of co-development and ceased cost-sharing activities in the first half of 2024.
XNCR filed a Form 144 reporting a proposed sale of 1,767 common shares dated 03/05/2026.
The filing also lists securities sold during the past three months: 1,492 shares on 03/03/2026 (proceeds $17,747.49) and 3,244 shares on 03/05/2026 (proceeds $36,480.40).
Bassil I. Dahiyat reported sales of common stock in relation to restricted stock vesting and open-market dispositions. The entry lists three transactions: 12/19/2025 sale of 114,377 shares, 03/03/2026 sale of 6,758 shares, and 03/05/2026 sale of 14,870 shares. The filing also records a restricted-stock vesting of 6,606 shares on 03/05/2026.
XNCR insider filing reports sales of company common stock by John Desjarlais. The filing lists securities to be sold: 2,502 common shares tied to restricted stock vesting on 03/05/2026 as compensation. It also discloses three reported sales during the past three months: 73,367 shares on 12/19/2025 for $11,534,819.99, 2,663 shares on 03/03/2026 for $31,676.65, and 4,118 shares on 03/05/2026 for $46,308.97.
XNCR reports an insider notice to sell 3,244 common shares related to Restricted Stock Vesting scheduled 03/04/2026.
The filing also shows a prior sale of 1,492 common shares on 03/03/2026 by Celia E. Eckert, listed in the three‑month sales section.